Home → News → Clinical Trials → Archive

Clinical Trial News Archive

Get news By email or subscribe to our News feeds.

All News Consumer Pharma New Drugs Pipeline Clinical Trials

May 2009

May 4

Alimera Sciences Announces Presentation of Data From the 12-Month Interim Readout of the Human PK Iluvien Study at ARVO 2009 Annual Meeting Tranzyme Pharma's Successful Phase 2 Postoperative Ileus Trial Results to be Presented at the American Society of Colon and Rectal Surgeons 2009 Annual Meeting Onset Therapeutics Announces Release of Study Results Demonstrating That ANESTAFOAM (Lidocaine 4% Foam) Reduces Pain Associated with Common Dermatologic Procedures Rexahn Reports Positive Preliminary Findings in Zoraxel Clinical Trial to Treat Erectile Dysfunction SuperGen's MP-470 Demonstrates Clinical Benefit in Lung Cancer Patients TransMolecular Presents New Information on Distinct Anti-Angiogenic Mechanism-of-Action of TM601 Narcolepsy is an Autoimmune Disorder, Stanford Researcher Says Fovea Reports Positive Results with Prednisporin in Persistent Allergic Conjunctivitis Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial Discovery Labs' KL4 Surfactant Shows Physiologic and Survival Benefit in a Preclinical Model for Severe Respiratory Condition -- Acute Lung Injury Inspire Announces Poster Presentations at 2009 Association for Research in Vision and Ophthalmology Annual Meeting Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology Pulmo BioTech Inc. Announces Paper to be Presented at Symposium Spotlight on Rosacea Advance - May Issue of Journal of Drugs in Dermatology Features Pyratine XR Clinical Study Rexahn Reports Positive Preliminary Phase IIa Findings in Zoraxel Clinical Trial to Treat Erectile Dysfunction Sciele Pharma and Plethora Solutions Announce Encouraging Results from European Phase III Study on PSD502 First Oral Drug for Uveitis Reduces Both Inflammation and Recurrence Rate in Potentially Blinding Eye Disease, Reports Lux Biosciences Positive Results for Ophthotech's Novel Therapy for Wet AMD - Study of Anti-PDGF and Anti-VEGF Therapy Shows Significant Neovascular Regression and Enhanced Visual Outcome Results Shown in BioCancell Compassionate Use Trial Using BC-819 for Treatment of Renal Cancer

May 6

Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome Study Reported Tadalafil Taken Once Daily Improved Erectile Function in Men with ED and Sexual Quality of Life in Couples Metabasis Therapeutics Announces Late-Breaking Abstract on MB07803 Trial Results Accepted for Presentation at the American Diabetes Association Meeting BioInvent Reports Positive Phase I Results for BI-204, in Development for Prevention of Cardiovascular Conditions Associated with Atherosclerosis Creative MediaWorks Goes Platinum! Hypertension: Information Technology to Improve Blood Pressure Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases Pharmaceutical Promotion At Its Productivity Frontier Lipoxen Positive Ph I EPO Trial Results Inotek Pharmaceuticals Presents Preclinical Data in Support of Novel Glaucoma Candidate, INO-8875 at ARVO SCORR Marketing Named Agency of Record by Skilled Care Pharmacy Resolvyx Presents Data Demonstrating Potential for Resolvin Therapeutics to Treat Corneal and Retinal Eye Diseases at ARVO 2009 Meeting Burzynski Research Institute Announces Positive Results of Phase II ANP Clinical Trial

May 8

Archimedes Pharma announces ground breaking phase III data showing NasalFent to be superior to the standard of care for breakthrough cancer pain New study results further support the evidence that the HPV vaccine Gardasil will provide long-lasting protection The four-type HPV vaccine Gardasil demonstrates real life benefits Studies of Gardasil, Merck's Cervical Cancer Vaccine, and HPV 16 Vaccine Component of Gardasil Presented at International Papillomavirus Conference New Data for GlaxoSmithKline’s Vaccine, Cervarix, Presented at IPV Conference Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results New Data Shows Blood Pressure Reduction Therapy with Benicar and Benicar HCT Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure New Data Shows Azor (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure Photo: Levemir Once-Daily Substantially Lowered Average Blood Sugar Levels of Patients with Type 2 Diabetes in Titrate Study Rapaflo (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days Juvaris BioTherapeutics' Universal Influenza Vaccine Protects from Lethal H1N1 and H3N2 Challenges in Pre-Clinical Studies

May 14

Mesoblast Limited (ASX:MSB) Announce Heart Muscle Function Improved Significantly After Single, Lowest-Dose Injection Of "Off-The-Shelf" Stem Cells In Patients With Heart Failure STINSON Brand Innovation, Inc. Celebrates 5 Years in Business Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS Synta Announces Elesclomol Phase 3 Melanoma Data to be Featured in Oral Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) Aradigm Presents Phase 2 Data on Inhaled Liposomal Ciprofloxacin in Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis at 2009 International Conference of the American Thoracic Society Benefits of Catheter Ablation with the NAVISTAR THERMOCOOL Catheter Sustained for One Year in the Treatment of Symptomatic, Paroxysmal Atrial Fibrillation Study Shows Chemotherapy Improves Survival Among Older Breast Cancer Patients Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa

May 18

VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients APF530 Phase 3 Data for Chemotherapy-Induced Nausea and Vomiting to be Presented at American Society of Clinical Oncology 2009 Annual Meeting BioLineRx Presents Data Demonstrating the Potential for BL-1020 to Improve Cognitive Deficits in Preclinical Models at Society of Biological Psychiatry 64rd Annual Scientific Convention & Meeting and Provides EAGLE Phase 2b Update Can-Fite Announces Positive Results From Its Phase II Trial Treating Keratoconjunctivitis Sicca (Dry Eye Syndrome) With CF101 Altair Therapeutics Reports Successful Completion of Phase I Study of Inhaled AIR645 Ardea Biosciences to Present Preclinical and Phase 1 Data on its Lead Gout Product Candidate, RDEA594, at the Annual European Congress of Rheumatology Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis ImmunoGen, Inc. Announces Trastuzumab-DM1 Presentations at the 2009 American Society for Clinical Oncology Annual Meeting Amgen Highlights Data to Be Presented at ASCO Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting Shire Announces Study Results of the Effects of INTUNIV (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology

May 19

Two Studies at AACE 2009 Annual Meeting Highlight Effects of Welchol (colesevelam HCl) on Blood Glucose and LDL-C in Patients with Type 2 Diabetes Two Targeted Therapies Likely Better Than One in Patients with Aggressive Lymphoma, Mayo Clinic Researchers Say Trius Presents New Data on Torezolid Antibiotic for Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting Santhera's US Phase III IONIA Trial in Friedreich's Ataxia Misses Primary Endpoint AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting ChemoCentryx's Traficet-EN Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009 Provectus Reports on Presentation of Chemoablation of Metastatic Melanoma from Joint Meeting of 7th World Congress on Melanoma and 5th Congress of the European Association of Dermato-Oncology Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting Cylene to Announce New Data on Its First-in-Class Oral CK2 Inhibitor Against Cancer at BIO Conference NEVO Sirolimus-Eluting Coronary Stent Yields Superior Results to Taxus Liberte Stent in Pivotal Clinical Trial Dynavax Announces Data Presentations at American Thoracic Society Medical Conference New Data from ENDEAVOR-II Challenges Conventional Wisdom on Drug-Eluting Stents In Patients with Heart Attacks, CYPHER Sirolimus-Eluting Coronary Stent Results Sustained out to Four Years Compared to Bare Metal Stents Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain Altair Therapeutics Reports Successful Completion of phase I study of Inhaled AIR645 ATS bosentan in combination with tadalafil Basilea Pharmaceutica Ltd. (CH) - Basilea presents new efficacy data on BAL30072, its novel antibiotic against Gram-negative bacteria Bayer Schering Pharma presents positive results of phase II study with Riociguat Velcade (Bortezomib) for Injection and Pipeline Data to Be Highlighted at American Society of Clinical Oncology Annual Meeting Addition of Lyrica Significantly Improved Generalized Anxiety Disorder Symptoms in Patients Who Responded Only Partially to Previous GAD Treatments Upcoming BioAlliance Pharma's Presentations at International Conferences on Infectious Diseases and Oncology Continued Growth Drives Move at Mc|K Healthcare Kamada Presents New Data on its Alpha-1 Antitrypsin at the American Thoracic Society Annual Meeting Drug That Targets Vasculature Growth Attacks Aggressive Thyroid Cancer, Mayo Clinic Researchers Report

May 20

Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) Blue Spoon Consulting Publishes White Paper: Pharmaceutical Industry Strategy for a Global Economic System Prospect Therapeutics, Inc.'s GCS-100 Exhibits a Low Toxicity Profile in Cancer Patients Genzyme and Isis Announce that Mipomersen Phase 3 Study in Patients with Homozygous Familial Hypercholesterolemia Met Primary Endpoint Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial Results of Phase III Study on Labopharm's Novel Antidepressant Published in Psychiatry (Edgemont) Journal NicOx presents phase 3 quality of life data for naproxcinod at ISPOR Nevo Sirolimus-Eluting Coronary Stent Yields Superior Results to Taxus Liberte Stent in Pivotal Clinical Trial

May 21

Antisoma plc (UK) - Phase II trial of ASA404 published in Lung Cancer Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia TransMolecular Announces Presentation of Data Highlighting Anti-angiogenic and Tumor-targeting Properties of TM601 at ASCO Annual Meeting Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association Somaxon Pharmaceuticals Presents Analyses of Silenor Clinical Data at the American Psychiatric Association Annual Meeting Phase III Data Show Novartis Investigational Bronchodilator QAB149 Significantly Improves Lung Function Over Current Treatments in COPD Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial Abbott's XIENCE V Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data In Patients With Schizophrenia SYNTAX Substudy Shows Positive Outcomes for Left Main Patients Treated With TAXUS Express2 Stent System PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents

May 26

Seattle Genetics to Present SGN-35 and Lintuzumab Clinical Data at the European Hematology Association Congress Boceprevir eliminated Hep C virus in unprecedented number of patients Astex reports positive data from its Phase I study of AT9283 at the ASCO Annual Meeting 2009 Widely Used Cancer Drug Bevacizumab Associated with Significantly Increased Risk of Gastrointestinal Perforation The Quality and Purity of Biosimilar Epoetin Zeta (Retacrit) is Demonstrated Through Comparative Analysis with Epoetin Alfa - Presented at WCN 2009 Cytheris Announces Publication of Preclinical Study in Nature Medicine Showing Combination of Interleukin-7 with Viral Vaccine Boosts Immunity to Tumors MAP Pharmaceuticals Phase 3 Trial of Levadex Migraine Product Candidate Meets All Four Primary Endpoints New Study Evaluating the ADHD Medication VYVANSE (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) Medinox Announces Clinical Results of Naproxen Prodrug OSI Pharmaceuticals to Provide a Summary of Data Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting Scientific Data Relating to Cinryze Presented at 6th Annual C1 Inhibitor Deficiency Workshop Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009 New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal NanoGuardian Partners with SDI on Closed-Loop Protection Two-Year Data Reinforce Effect of Actemra (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients First in class uveitis therapy -- Ph3 results highlighted at IOIS Proscape Technologies Congratulates Connect Tech, a Division of Draftfcb Healthcare, on Becoming a Gold Certified Content Partner

May 27

Addex Pharmaceuticals (CH) - Glutamate Receptor "mGluR5" Implicated in GERD Nycomed Reports a Solid Start to 2009 Affymax Reports Phase 2 Clinical Trial Data Supporting Hemoglobin Increases with Once-Per-Month Hematide Regardless of Patient Baseline Renal Function Synergy Pharmaceuticals to Present Phase I Volunteer Study on SP-304 Investigational Drug to Treat GI Disorders at Upcoming Conference Oncothyreon announces closing of $11.1 million registered direct financing Tugboat Consulting Group Announces Key Collaborations To Offer Unique Marketing Products CombinatoRx Reports Positive Phase 2 Trial Results for CRx-401 Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease GTC Biotherapeutics Announces One-for-Ten Reverse Stock Split Genta Incorporated Announces Postponement of Special Stockholders Meeting Spectrum Pharmaceuticals to Raise $20 Million from Institutional Investors at $5.11 Per Share, the Closing Bid Price on Tuesday, May 26, 2009 Arno Therapeutics Announces Three Poster Presentations at ASCO Annual Meeting Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009 Genaera Receives Non-Compliance Notice from Nasdaq Sarah Cannon Research Institute to Present Latest Cancer Research Data at National Clinical Oncology Conference Metastatic Colon Cancer: In a Randomized Phase II Clinical Study, Antineoplaston Therapy Doubled the 5-Year Survival Rate Following Curative Resection of Hepatic Metastases

May 28

SCORR Marketing Wins Nine Awards in National Marketing Competitions Tongjitang Chinese Medicines Company to Announce First Quarter 2009 Financial Results on June 3, 2009 Biofrontera AG (DE) - Biofrontera raised 3 Million Euro in capital round GPC Biotech AG (DE) - GPC Biotech Reports Financial Results for First Quarter 2009 New Study Results Published Compare Abraxane to Taxotere Minster Pharmaceuticals Plc Preliminary Results AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types CuraGen to Present CR011-vcMMAE Data at ASCO Peregrine Pharmaceuticals Reports Progress in Cotara Brain Cancer Clinical Program EpiCept Announces Presentation of New Crinobulin Data at 2009 American Society of Clinical Oncology Annual Meeting GTx Announces Toremifene 80 mg Phase III ADT Clinical Trial Data to be Presented at the Annual Meeting of the American Society of Clinical Oncology GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants Oculus Innovative Sciences Announces Fiscal Fourth Quarter Financial Results and Corporate Update Release and Conference Call Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting Dana-Farber Cancer Institute Presents Results of GlycoMimetics' Lead Drug Candidate in Models of Multiple Myeloma at American Society of Clinical Oncology Annual Meeting BioMS Medical to Present at the 2009 Symposium for the Canadian Society for Pharmaceutical Sciences Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer Valeant Plans Senior Notes Offering Proteon Therapeutics Completes Second Closing of Equity Financing; Raises Total Series B to $50 million Results and Additional Analyses From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009 Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer MethylGene Reports Favorable Kinase Inhibitor Data at ASCO Meeting Talecris data shows that concentrated form of Prolastin is safe and tolerable; potentially cuts infusion times in half for patients with AAT deficiency

May 29

Phase 1 Study for Halozyme's Insulin-PH20 Published, Highlights Findings for Faster Acting Insulin Formulations Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Fiscal Year 2009, Updates on FDA Inspection Lipoxen Raises £2.9m, Led by Baxter Plus Director's Dealings Valeant Pharmaceuticals International Sr. Unsecured Debt Ratings Assigned; CCR Affirmed; Outlook Positive New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction Ore Pharmaceuticals Inc. Announces NASDAQ Deficiency Notice Gloucester Pharmaceuticals to Present New Data from Two Studies on Romidepsin at ASCO Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO Change in the Number of Shares in Vitrolife AB (publ) NPS Reports Three Teduglutide Abstracts Accepted for Presentation at Digestive Disease Week Conference Vion Pharmaceuticals to Present Data on Onrigin at the ASCO Annual Meeting Biothera Releases Colorectal Cancer Study Results at ASCO YM Biosciences Announces Results Of Randomized Nimotuzumab Study To Be Presented In A Poster At ASCO Annual Meeting New Study Results Verify That PNH Cells Are Found in Majority of Patients with Bone Marrow Failure Syndromes Novo Nordisk: New study directly comparing insulin delivery devices shows that Next Generation FlexPen® has a significantly lower injection force than SoloStar® and KwikPen® Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Advanced Breast Cancer Pfizer Invites Public to View and Listen to Webcast of June 12 Conference Call with Analysts at EULAR AV-951 Demonstrates Prolonged Progression-Free Survival and Excellent Safety Profile in Patients with Advanced Kidney Cancer; Phase 2 Data Presented at ASCO

Clinical Trial Results Archive

2005

April

More News Resources

(web1)